Biomerica (BMRA) vs Cardio Diagnostics (CDIO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Biomerica is the larger company by market cap ($8.6 million vs $5.6 million), about 1.5 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Head-to-head
| Metric | BMRA | CDIO |
|---|---|---|
| Share price | $1.88 | $1.89 |
| Market cap | $8.65M | $5.59M |
| 1-day change | -1.05% | -4.06% |
| YTD return | -24.21% | — |
| 1-year return | -32.75% | — |
| 5-year return | -95.69% | — |
| Forward P/E | 4.82 | — |
| EPS (TTM) | $-1.30 | $-2.91 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $3.21 | $7.91 |
| 52-week low | $1.45 | $0.97 |
| Distance from 52-week high | -41.43% | -76.11% |
| Average volume | 70.89K | 55.63K |
| Shares outstanding | 4.60M | 2.96M |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
BMRA vs CDIO FAQ
Which is bigger, Biomerica or Cardio Diagnostics?
Biomerica (BMRA) is larger, with a market capitalization of $8.65M compared with $5.59M for Cardio Diagnostics (CDIO).
Are Biomerica and Cardio Diagnostics in the same industry?
Yes. Both are classified in the Biotechnology: In Vitro & In Vivo Diagnostic Substances industry within the Health Care sector.